Artivion Beheer
Beheer criteriumcontroles 4/4
De CEO Artivion is Pat Mackin, benoemd in Sep2014, heeft een ambtstermijn van 10.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.18M, bestaande uit 24.4% salaris en 75.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.59% van de aandelen van het bedrijf, ter waarde $ 17.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 8.1 jaar.
Belangrijke informatie
Pat Mackin
Algemeen directeur
US$3.2m
Totale compensatie
Percentage CEO-salaris | 24.4% |
Dienstverband CEO | 10.2yrs |
Eigendom CEO | 1.6% |
Management gemiddelde ambtstermijn | 4.3yrs |
Gemiddelde ambtstermijn bestuur | 8.1yrs |
Recente managementupdates
Recent updates
When Should You Buy Artivion, Inc. (NYSE:AORT)?
Nov 07Returns At Artivion (NYSE:AORT) Are On The Way Up
Sep 28Estimating The Intrinsic Value Of Artivion, Inc. (NYSE:AORT)
Sep 06Is Artivion (NYSE:AORT) A Risky Investment?
Jun 28Data-Driven Growth Fuels More Upside For Overlooked Artivion
Jun 21Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 08Is Artivion (NYSE:AORT) Using Too Much Debt?
Jan 13Artivion Stock: A First Assessment
Dec 27Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump
Nov 23Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025
Oct 13Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
Jul 20Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher
May 10Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet
Mar 09Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M
Feb 16Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold
Dec 18Artivion (NYSE:AORT) Is Making Moderate Use Of Debt
Sep 29Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver
Sep 27Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M
Aug 04Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$842k |
Jun 30 2024 | n/a | n/a | -US$8m |
Mar 31 2024 | n/a | n/a | -US$10m |
Dec 31 2023 | US$3m | US$776k | -US$31m |
Sep 30 2023 | n/a | n/a | -US$24m |
Jun 30 2023 | n/a | n/a | -US$28m |
Mar 31 2023 | n/a | n/a | -US$29m |
Dec 31 2022 | US$7m | US$750k | -US$19m |
Sep 30 2022 | n/a | n/a | -US$41m |
Jun 30 2022 | n/a | n/a | -US$17m |
Mar 31 2022 | n/a | n/a | -US$15m |
Dec 31 2021 | US$5m | US$728k | -US$15m |
Sep 30 2021 | n/a | n/a | US$2m |
Jun 30 2021 | n/a | n/a | -US$12m |
Mar 31 2021 | n/a | n/a | -US$13m |
Dec 31 2020 | US$3m | US$606k | -US$17m |
Sep 30 2020 | n/a | n/a | -US$14m |
Jun 30 2020 | n/a | n/a | -US$11m |
Mar 31 2020 | n/a | n/a | -US$5m |
Dec 31 2019 | US$6m | US$689k | US$2m |
Sep 30 2019 | n/a | n/a | US$2m |
Jun 30 2019 | n/a | n/a | US$3m |
Mar 31 2019 | n/a | n/a | US$709k |
Dec 31 2018 | US$3m | US$660k | -US$3m |
Sep 30 2018 | n/a | n/a | -US$5m |
Jun 30 2018 | n/a | n/a | -US$5m |
Mar 31 2018 | n/a | n/a | -US$2m |
Dec 31 2017 | US$3m | US$640k | US$4m |
Compensatie versus markt: De totale vergoeding ($USD 3.18M ) Pat } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.21M ).
Compensatie versus inkomsten: De vergoeding van Pat is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Pat Mackin (57 yo)
10.2yrs
Tenure
US$3,176,413
Compensatie
Mr. James Patrick Mackin, also known as Pat, has been the Chief Executive Officer and President of Artivion, Inc. (formerly known as CryoLife, Inc.) since September 02, 2014 and has been its Chairman since...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman | 10.2yrs | US$3.18m | 1.59% $ 18.0m | |
Executive VP of Finance | less than a year | US$1.64m | 0.19% $ 2.1m | |
VP & Chief Accounting Officer | 18.3yrs | US$1.06m | 0.33% $ 3.8m | |
Senior VP | 9.6yrs | US$993.72k | 0.39% $ 4.4m | |
Senior VP & Chief Commercial Officer | less than a year | US$953.41k | 0.38% $ 4.2m | |
VP of Human Resources & Chief Human Resources Officer | 5.3yrs | geen gegevens | 0.081% $ 920.7k | |
Senior VP of Clinical Research & Chief Medical Officer | 3.7yrs | US$1.61m | 0.20% $ 2.2m | |
Vice President of Research & Development | 1.4yrs | geen gegevens | 0.032% $ 358.8k | |
Vice President of Global Operations | 4.3yrs | geen gegevens | 0.061% $ 693.3k |
4.3yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AORT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Chairman | 10.1yrs | US$3.18m | 1.59% $ 18.0m | |
Independent Director | 8.1yrs | US$217.50k | 0.15% $ 1.7m | |
Independent Director | 20.9yrs | US$230.00k | 0.34% $ 3.9m | |
Independent Director | 3.1yrs | US$217.50k | 0.081% $ 922.0k | |
Independent Director | 20.9yrs | US$235.00k | 0.34% $ 3.9m | |
Independent Presiding Director | 7.2yrs | US$265.00k | 0.11% $ 1.3m | |
Independent Director | 12.5yrs | US$215.00k | 0.29% $ 3.3m | |
Independent Director | 6.4yrs | US$220.00k | 0.10% $ 1.2m | |
Independent Director | 2.1yrs | US$210.00k | 0.060% $ 676.5k |
8.1yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AORT wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.1 jaar).